Torrent Pharmaceuticals Ltd · NSE:TORNTPHARM

Torrent Pharmaceuticals — Q4 FY2013-14 Earnings Presentation

31 slides from Torrent Pharmaceuticals's earnings presentation, 2014

  1. Slide 1: Investor Presentation Q4 FY 2013-14

    Investor Presentation Q4 FY 2013-14 1

  2. Slide 2: Caveat

    Caveat This information may contain certain forward-looking statements/ details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views expre

  3. Slide 3: Agenda

    AGENDA Performance over Period Financial Highlights Segmental Highlights Shareholding Pattern Facilities 3

  4. Slide 4: Performance Over Period

    torrent PHARMA Performance Over Period

  5. Slide 5: Torrent Pharma: Assets Across the Value Chain

    Torrent Pharma: Assets Across the Value Chain Domestic Sales International Research and Manufacturing and Acquisition Operations Development Marketing  Value-added  API + formulation  Broad and  Reach to over 70  Proposed generics facilities having differentiated countries with 16 acquisition o

  6. Slide 6: 5 Years Performance Snapshot

    5 Years Performance Snapshot 13000 6000 5 Years CAGR 664 Revenue 22% 12000 PBT 35% 844 11000 PAT 29% 5000 Market Cap 51% 435 10000 4184 582 4000 8861 9000 270 286 359 8000 3212 3000 231 342 7000 2695 347 2226 5883 2000 6000 1916 5319 4893 5000 4613 1000 4000 3000 0 09-10 10-11 11-12 12-13 13-14 6 Ma

  7. Slide 7: Key Territories 5 Years Performance

    Key Territories 5 Years Performance 4000 5 Years CAGR 388 Domestic 12% USA 69% 3500 930 Brazil 15% Europe 23% 328 3000 ROW 24% 246 650 2500 533 205 542 776 2000 162 502 449 477 404 1500 355 355 216 1161 308 114 1000 94 1024 909 834 725 500 0 Domestic USA Brazil Europe ROW 7

  8. Slide 8: 5 Years Ratios

    5 Years Ratios EBITDA to sales PBT to sales PAT to sales RoCE ROE 35% 30% 28% 24% 26% 33% 32% 30% 28% 26% 12% 13% 14% 14% 12% 18% 18% 18% 16% 16% 23% 22% 21% 21% 21% 09-10 10-11 11-12 12-13 13-14 8

  9. Slide 9: Financial Highlights

    torrent PHARMA Financial Highlights

  10. Slide 10: Revenue Composition

    Revenue Composition FY 13-14 Revenues : ` 4184 crores Others Brazil CRAMS ROW 20% 8% 1% 16% India 28% USA 29% Europe 35% International 63% • Domestic: 5 Year CAGR : 12% • International: 5 Year CAGR: 26% 10

  11. Slide 11: Revenue Progression

    Revenue Progression ` Cr Q4 Q4 Particulars 13-14 12-13 13 - 14 12 - 13 India 256 218 1,161 1,024 Gwth % 17% 13% 13% International 882 524 2,629 1,827 Gwth % 68% 44% 44% USA 400 92 776 355 Brazil 128 133 533 502 Europe 251 211 930 650 ROW * 103 88 390 321 Contract Manufacturing 80 94 323 300 Gwth % -

  12. Slide 12: P&L

    P&L ` Cr Q4 Q4 Particulars 13-14 12-13 13 - 14 12 - 13 Revenues 1,225 871 4,184 3,212 COGS 320 243 1,243 926 % Revenues 26% 28% 30% 29% SG&A Spend 347 244 1,248 970 % Revenues 28% 28% 30% 30% Employee Cost 208 164 741 623 % Revenues 17% 19% 18% 19% EBITDA 350 220 952 693 % Revenues 29% 25% 23% 22% D

  13. Slide 13: Balance Sheet

    Balance Sheet ` Cr Particulars 31-Mar-13 % 31-Mar-14 % ∆ EQUITY AND LIABILITIES Shareholders funds 1,422 69% 2,001 67% 580 Minority Interest 0 0% 0 0% 0 Non-current liabilities 651 31% 992 33% 341 TOTAL 2,073 100% 2,994 100% 921 ASSETS Net Fixed Assets 1,105 53% 1,409 47% 304 Loans & Advances 63 3%

  14. Slide 14: Segmental Highlights

    torrent PHARMA Segmental Highlights

  15. Slide 15: Business Segment: India

    Science Specialties driven strategy Rx driven hygiene Business Segment : India 15

  16. Slide 16: Torrent Therapy Performance

    Torrent Therapy Performance Torrent Therapy salience Rest • Among the top cos. In Cardiac, CNS, GI Nutraceutic Therapy als/ WHC 6% Anti Diab 2% • Cardiac, Diabetes, CNS, GI and Derma markets 6% – Higher than CM Growth Anti-Infect. Cardiac 10% 37% • Realignment of divisions with increased focus on sp

  17. Slide 17: Torrent Top Brands

    Torrent Top Brands Top 10 Torrent Brands* – Value Rs Cr 87 Value Rs. Cr. 72 62 60 59 45 45 43 39 39 NEXPRO DEPLATT NIKORAN NEBICARD DILZEM AZULIX ALPRAX DOMSTAL TOPCEF VELOZ Brand Molecule Brand MS% Gr% Gr% NEXPRO 35% 29 19 DEPLATT 19% 24 6 NIKORAN 52% 29 15 NEBICARD 44% 26 15 DILZEM 70% 18 6 AZULIX

  18. Slide 18: India

    India ` Cr Q4 Q4 India 13-14 12-13 13 - 14 12 - 13 Revenues 256 218 1161 1024 % Growth 17% 13% Q4 FY 14 Highlights • IPM growth: 7%, Covered Market growth: 6%, Torrent growth: 16% • Torrent 9th largest contributor to IPM’s incremental value • Productivity growth 2013-14: around 18% to 20% Growth dri

  19. Slide 19: Business Segment: International

    Business Segment : International 19

  20. Slide 20: USA Presence: ANDAs approved

    USA Presence ANDAs approved 2007 2008 2009 2010 2011 2012 2013 Till Mar'14 Metformin Amlodipine Levetiracetam Cetirizine Pantoprazole DR Tabs Quetiapine IR Pioglitazone Telmisartan + Hctz Sertraline Risperidone Lamotrigine Losartan + Hctz Donepezil Levetiracetam XR Pio. + Met. Telmi. + Amlo. Citalop

  21. Slide 21: USA: Torrent among top players on several products

    USA ISMN ER 2.14% CITALOPRAM 6.16% 4% 3.54% 2.78% AMNEAL PHARM TORRENT PHARM 6.62% TORRENT PHARM KREMERS URBAN CAMBER PHARM 13.65% 32.92% 41.25% AUROBINDO PHARM WEST WARD 11.01% MYLAN HERITAGE PHARMA 19.35% 34.95% CARACO PHARM 21.65% OTHERS TEVA PHARMACEUTICA OTHERS 2.43% LOSARTAN HCTZ 1.83% ZOLPIDE

  22. Slide 22: USA Revenues

    USA ` Cr Q4 Q4 USA 13-14 12-13 13 - 14 12 - 13 Revenues 400 92 776 355 % Growth 337% 119% Q4 FY 14 Highlights • Constant Currency Growth 284%, driven by Duloxetine • Duloxetine (Cymbalta) launched as FTF has market share of 8.9% (IMS Mar’14) Growth drivers • As of Mar-14 the Company has 48 ANDA appr

  23. Slide 23: Brazil: Largest Indian player

    Brazil Gliclazide Donepezil 5% 5% TORRENT - EPEZ 6% SERVIER - DIAMICRON PFIZER - ERANZ 39% MR TORRENT - AZUKON 25% SANDOZ - ZILEDON 61% 59% MR CRISTALIA - LABREA Indapamide SR Lamotrigine 3% 3% TORRENT - INDAPEN SR TORRENT - LAMITOR 4% 7% 7% SERVIER - NATRILIX SR 9% GSK - LAMICTAL 45% SERVIER - NATR

  24. Slide 24: Brazil Revenues

    Brazil ` Cr Q4 Q4 Brazil 13-14 12-13 13 - 14 12 - 13 Revenues 128 133 533 502 % Growth -4% 6% Q4 FY 14 Highlights • Flat on constant currency basis • Covered Market Growth (excluding Government reimbursement programme) is 10%, Torrent growth 9% as per IMS in units term. Growth drivers • Pipeline : 1

  25. Slide 25: Europe Revenues

    Europe ` Cr Q4 Q4 Europe 13-14 12-13 13 - 14 12 - 13 Revenues 251 211 930 650 % Growth 19% 43% Q4 FY 14 Highlights • Flat on constant currency basis • Europe (Dossier Business) & Romania key contributors to growth Growth drivers • New Products going off patent and Therapy coverage expansion in Heuma

  26. Slide 26: ROW Revenues

    ROW ` Cr Q4 Q4 ROW 13-14 12-13 13 - 14 12 - 13 Revenues 108 90 388 328 % Growth 19% 19% Q4 FY 14 Highlights • Revenue growth of 9% on constant currency basis. Growth drivers • Middle East/ Africa Region Delivering the growth being an upcoming market • Continuous registration of new products from the

  27. Slide 27: Shareholding Pattern

    torrent PHARMA Shareholding Pattern

  28. Slide 28: Shareholding Pattern as on March 31, 2014

    Shareholding Pattern; as on March 31, 2014 • Total shares outstanding : 16.92 crores • Free Float (shares) : 4.82 crores FIIs 12% Mutual Funds 8% Promoter & Individual & Promoter others group 8% 72% CAGR Return of more than 20% since IPO 28

  29. Slide 29: Facilities

    torrent PHARMA Facilities

  30. Slide 30: Expansion Plan

    Expansion Plan Dahej SEZ • Nature: Formulation & API Capacity Enhancement • Project Cost: ` 1100 crores • Planned capacities: 80 TPA plus 14,000 million tablets / capsules p.a. • Timelines for completion: • Phase I: Project cost of ` 750 crores, First Regulatory Approval: Q2’14-15 • Phase II: Projec

  31. Slide 31: Thank You

    Thank You 31

Torrent Pharmaceuticals — Q4 FY2013-14 Earnings Presentation on 6ix